Posts Tagged ‘obesity treatment’

Much of the world seems stuck on chasing ever higher numbers for weight loss. But clearly we need better targets for innovation in obesity and metabolic health. At the recent BIO Investment & Growth Summit, Immunis CEO Hans Keirstead came to tell us the answer lies in the health of our muscles. He has a […]

Trends for metabolic and bariatric surgery are still wobbly as GLP-1 utilization continues to grow. This much is quite clear from a new research letter in JAMA Surgery. What is less clear is any consensus on where the trends will go as health systems and people living with obesity confront the reality of obesity as […]

This has been a long time coming and the path to get here has been tortured. Nature Medicine published new results of a rigorous phase two study with bimagrumab and semaglutide for obesity. The results are striking because the combination of these two drugs produces improvements in body composition we have never seen before in […]

Neglect is a strong word. But if we want to be honest about the excessive emphasis on weight loss in obesity care, it seems appropriate. Research on new therapies for obesity have long neglected the challenge of maintenance therapy for this chronic disease. A new study in Obesity makes this gap plain to see. A […]

Are we on our way to progressing beyond weight loss as the primary end point for judging the value of new medicines in obesity? On this closing day of Obesity Care Week, topline results for a promising new obesity medicine – petrelentide – prompts us to reflect on this question. We suspect AI was making […]

Today, three of the leading voices for obesity care are releasing new guidance for obesity medicines in ongoing therapy. The Obesity Society, Obesity Medicine Association, and Obesity Action Coalition all came together in support of this important new guidance. Alongside its publication in the journal Obesity, Beverly Tchang and Donna Ryan offer a “humbling call […]

In Lancet yesterday, Julio Rosenstock and colleagues published the results of a head-to-head comparison of orforglipron versus oral semaglutide in adults with type 2 diabetes and a BMI greater than 25. Headlines would have you believe this was a clear win for orforglipron over semaglutide. But it’s not quite that simple. The Study Details The […]

From day one of Novo Nordisk launching Wegovy (semaglutide) tablets, we have seen a sharp contrast. Experts have been standing back with a collective yawn, while real world experiences seem to favor these oral obesity meds. “I haven’t prescribed them once,” confided a friend who is a nationally recognized expert in obesity medicine. That caution, […]

Many surprising twists await us in the interaction between food marketing and the rise of GLP-1 medicines for treating obesity. Eating habits are changing for the people who take them. In part, this is happening because of a reduction in food noise – intrusive, persistent, and unpleasant thoughts about food. But the effects of this […]

For as long as we can remember, people have been swooning over the magic of intermittent fasting. The hype told us it was a natural way to eat whatever we want and lose weight. That hype even suggested it could help us live longer and prevent cancer! Pish posh says the Cochrane Collaboration. The sum […]